Friday, 17 February 2017

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline, Forecast and Market Analysis 2017 Industry Research Report

ResearchMoz added Latest Research Report titled " PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 " to it's Large Report database.

DelveInsights, PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

Request for Sample PDF of Premium Research Report with TOC:

  • The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for PD and PD-L1 inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
  • The report also gives the information of dormant pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Read All Pharmaceutical Market Research Reports @

Table of Content

Executive Summary
Programmed Death 1 (PD-1)
Programmed Death Ligand 1 (PD-L1)
Role of PD-1 and PD-L1 pathways
MOA of PD-1 and PD-L1 inhibitors
Significance of PD-1 and PD-L1 inhibitors
PD-1 and PD-L1 Active Therapy Areas & Epidemiology
Metastatic Renal Cell Carcinoma
Squamous Cell Carcinomas of the Head and Neck
Metastatic Colorectal Cancer
Non-Small Cell lung cancer
Biomarkers - PD-1 and PD-L1 inhibitors
Market Overview
Comparative Analysis of Pipeline &Marketed Drugs
Marketed Product of PD-1 and PD-L1 drugs Overview
Marketed Drug Candidate Profiles
Marketed Drugs Sales
Details of Patent Expiry of Marketed Drugs
Current and Future Market for PD and PD-L1 inhibitors
Challenges and Barriers associated with use of PD and PD-L1 inhibitors
PD-1/PD-L1Combinations Creating Boom
Pipeline Therapeutics

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at:

No comments:

Post a Comment